Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study

Table 2

Response (23 patients).

	CR	PR	SD	PD	RR
Overall	0	4	4	15	17.4% (95% CI, 1.9–32.9%)

CR: complete response; PR: partial response; SD: stable disease;
PD: progressive disease; RR: response rate; CI: confidence interval.